logo
A looming dairy drought will stunt the world's growth

A looming dairy drought will stunt the world's growth

Business Times21-07-2025
IT IS every baby's first food, and we cannot get enough of it.
The world produces close to a billion tonnes of milk each year – more than all the wheat or rice we grow. That lead is set to widen over the coming decade, with dairy consumption expected to grow faster than any other agricultural commodity. On a rapidly warming planet, this poses a host of problems.
Consider demand. There are more than half a billion people under the age of four in developing countries, and about a third of them suffer from stunting – short stature that is associated with health, educational and economic problems in later life. Most could benefit from the policy first proposed by Scottish nutritionist John Boyd Orr in the 1920s: provision of dairy products to give them a more nutritionally rich diet.
That is one of the main pillars of Indonesian President Prabowo Subianto's newly introduced free school meals programme, as my colleague Daniel Moss has written. Similar programmes have been set up in many states in India, as well as South Africa and Kenya.
In terms of human welfare, we should be welcoming this trend.
Dairy products are relatively expensive, and we consume more of them as we rise above the most basic subsistence levels. If South Asia, South-east Asia and sub-Saharan Africa are likely to see booming consumption over the coming decade, as the Organization for Economic Co-operation and Development forecast last week, it is largely a positive symptom of their long-awaited economic development.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
The problem comes when you start looking at supply. Milk is mostly being produced in the wrong places for the young stomachs that need it. More than 90 per cent of children under four are in developing countries – but the same nations produce barely half of the world's milk.
Europe alone represents a quarter of global output, and highly perishable dairy products are not much sold across borders. The total worldwide trade in whole milk powder, for instance – after a decade when China's hunger for baby formula upended the global dairy industry – accounts for about 2 per cent of raw milk. Even that limited commerce has been sufficient to upset local supply chains.
In New Zealand, often likened to the Saudi Arabia of dairy thanks to its dominance in exports, demand from South-east Asian importers drove whole milk powder prices to a three-year high in May, while butter inflation is running above 50 per cent.
With trade providing only limited relief, we are most likely to see shortages, as rising demand from developing countries is met with limited increases in supply.
The world's milk deficit will hit 30 million tonnes by 2030, the International Dairy Federation warned in April. The IFCN Dairy Research Network, a separate group, still sees a 10.5 million tonne shortfall by the same date. That dairy drought will push prices beyond the reach of those who most need it.
Climate change makes all of this worse. Rising temperatures will mean it is even harder for tropical and subtropical countries to be self-sufficient: Extreme heat can cut milk production by as much as 10 per cent, according to a study in the journal Science Advances earlier this month.
Milk is also a major culprit in global warming, as well as a victim of it. Dairy cattle emissions, mostly from methane-dense burps as cows digest grass, amount to 2.1 billion tonnes of carbon dioxide a year, equivalent to what is caused by two-thirds of all cars.
The shift to more production in developing nations will make this even worse. Pollution for each kilogram of raw milk in Africa and South Asia is three to four times higher than in developed countries, because the mechanised, intensive dairy farming practised in the rich world has a far lower carbon footprint.
What can be done to fix this? Wealthy nations whose appetite for plant-based alternatives appears to be wavering should recommit to their shift away from livestock-based food.
Far too much of our limited capacity to sustain dairy production is still being hogged by affluent populations, who have grown so jaded that we now use milk for luxuries like bodybuilding supplements as much as for basic nutrition.
Relatively prosperous developing countries like China and Brazil can also up their game by moving to more intensive farming. They could get by with a third of their current dairy herd if they raised yields to developed-world levels.
In India, the biggest dairy producer, the benefits could be even greater. Thanks to religious objections to the slaughter of cows after they stop producing, there are more than five million stray cattle roaming the streets, spreading disease, attacking people, getting hit by traffic and fuelling organised crime.
A smaller, more intensively raised herd would shrink this bovine epidemic. Greater dairying of buffalo, which already produce about half of India's milk and are not considered sacred, would also help.
One thing is certain, though: Exhorting poor countries to give up the nutritional benefits of dairy that their richer peers have enjoyed is repugnant, and bound to fail. If we want to reduce milk's carbon footprint, we are going to need to produce it more efficiently, rather than hoping the problem will just go away. BLOOMBERG
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SG60: Why ageing needs a new narrative in Singapore
SG60: Why ageing needs a new narrative in Singapore

Business Times

timea day ago

  • Business Times

SG60: Why ageing needs a new narrative in Singapore

Sixty years ago, Singapore was a young and rapidly developing nation. Life expectancy stood at just 65 years, and only 2 per cent of the population was aged 65 or older. Back then, national priorities focused on managing the high birth rates and laying the foundations for the future: building homes, expanding education, growing the economy and improving public health. Fast-forward to today, and Singapore is renowned for having one of the longest lifespans in the world, with life expectancy having risen to 83.5 years and the number of centenarians doubling between 2010 and 2020. The significant progress can be attributed to advances made in healthcare, easy access to medical care, and generally healthier lifestyles among Singaporeans. However, the jump in lifespans also poses a somewhat uncomfortable question. While we are living longer, are we living better? This question has never been more urgent, as Singapore, which is also one of the world's fastest-ageing societies, stands on the cusp of becoming a super-aged nation. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up By 2030, one in four residents will be aged 65 or above, and our old-age support ratio is projected to fall to 2.7. While lifespans have soared, healthspans – how long we live in good health – have not kept pace, with a stark 10-year gap between them. These trends seem to reflect the anxieties among Singaporeans. In a recent RySense survey, 79 per cent of respondents said that they do not look forward to growing old, citing concerns around poor health (80 per cent), cognitive decline (50 per cent), dependence on others (49 per cent), financial insecurity (40 per cent), and loneliness (25 per cent). On its own, longevity does not guarantee a good life. The real challenge, or rather I would posit an opportunity, for ageing societies such as Singapore is to improve 'living spans'. This means enhancing the quality of life in the additional years we now have; ensuring physical, mental, social, and financial well-being as we progress through life. This requires a shift in mindset. So far, much of the discourse on ageing has been framed negatively: a 'silver tsunami', a 'demographic time bomb', a strain on healthcare systems and the economy. But it is also an opportunity – to innovate, to redesign systems, to reimagine ageing and build a society where longer lives can truly be better lives. Seeing through a new lens: From deficit to possibility To move forward, we must first challenge the outdated assumptions and stereotypes about ageing. Too often, ageing is seen through the lens of deficit – a drain on resources, a challenge to be managed – but this view is both limiting and inaccurate. Today's seniors are increasingly healthy, educated and financially independent; many are choosing to remain economically and socially active – working, volunteering, travelling, contributing – in ways that benefit both themselves and society. Far from being a liability, this demographic shift presents enormous potential. Across the Asia-Pacific, the 'silver economy' is projected to be worth US$4.6 trillion by 2030. From healthcare and housing to financial services and wellness products, the longevity economy is a sunrise industry for businesses ready to innovate. More importantly, we must acknowledge the 'longevity dividend': the value that seniors bring to society through their wisdom, experience and resilience. They are not simply recipients of care; rather, they are an underutilised resource that can contribute as mentors, caregivers, volunteers, and leaders. Another misconception to leave behind is that ageing is a 'senior issue'. Today's youth face the possibility of outliving any generation before them, and will need to prepare to afford those years. Millennial and Gen X caregivers are already navigating the dual demands of ageing parents and children. Ageing doesn't begin at 65; it is a lifelong journey, shaped by decisions made by you and me at every stage of our life. Policies that support healthy ageing – preventive healthcare, lifelong learning, financial literacy, inclusive design – benefit everyone. As Dr Laura Carstensen of Stanford University put it: 'Longevity readiness is not about redesigning the world for older people. It's about redesigning our world so that longer lives are healthy and fulfilling at every stage.' Building on foundations: From readiness to leadership Thankfully, Singapore is not starting from scratch. The government, which recognised early on that ageing well doesn't happen by chance, has laid strong foundations through forward-looking policies and programmes that promote preventive care, active ageing, and community-based support. Age Well SG, in particular, is the most comprehensive to date: a S$3.5 billion national commitment to help seniors age well in the community, spanning housing options, living environment enhancements, social support and preventive health. The intent is clear: Singapore is not just preparing for longer lives, but for better ones. However, infrastructure and policy alone are not enough. Meaningful progress requires a whole-of-society approach, one where government, businesses and community work in concert. DBS' commitment to supporting the Republic's ageing agenda At DBS, we believe that businesses have a social licence and responsibility to uphold. This is rooted in our founding purpose – as the Development Bank of Singapore, nation-building has been central to our DNA and continues to guide us today. As the Republic transitions into a super-aged society, we are committed to supporting this by drawing on our core strengths to deliver long-term value for all. Financial health is a critical enabler of ageing well. Longer life expectancy is a positive outcome, but it comes with new pressures – caregiving responsibilities, ill health, loss of loved ones, or just keeping up one's lifestyle – that can strain finances. Without sufficient preparation, these moments can tip one into financial vulnerability. DBS Financial Wellness Series research earlier this year found that Gen Zs and millennials, aged 25 to 44, are falling behind their older counterparts in building their nest egg for their later years. This is even as they increasingly shoulder heavier liabilities, with their debts (home, car and credit-card loans) slightly outweighing their liquid assets. That's why the bank has long focused on helping Singaporeans build financial literacy and resilience across all life stages. Our customers from ages seven to 70 have access to tools and solutions that help enhance their financial wellness. These range from the POSB Smart Buddy smartwatches that track and inculcate spend and save habits, to digital wealth adviser tools in our digibank app to widen access to financial advice and help customers make better-informed money decisions. Together with partners such as the Infocomm Media Development Authority, our employee volunteers continue to drive digital and financial literacy workshops in the community. Beyond financial preparedness, ageing well also requires meeting fundamental needs such as nutrition, connections, and a sense of belonging. Yet for many seniors, especially those in vulnerable circumstances, these often remain out of reach. As part of our commitment to uplifting the lives and livelihoods of those with less, the DBS Foundation announced a S$7.3 million initiative this year to address the challenges of poor nutrition and social isolation. Over two years, this will benefit 6,000 low-income seniors across 12 ageing towns, providing them with regular access to nutritious meals and meaningful social interactions. This includes monthly engagements and quarterly grocery runs, supported by the bank's 14,000-strong workforce. DBS Foundation also works with like-minded partners to catalyse impact. We recently announced the four winners of our inaugural Impact Beyond Award – businesses with transformative solutions to help seniors age well, including Singapore's Buddy of Parents – and awarded funding totalling S$3 million to scale their efforts. In addition, we continue to tap the bank's network and our signature Impact Beyond summit and dialogue events to convene changemakers and spark cross-sector conversations and collaboration. The future is ours to shape Singapore's story has always been one of shared progress: building together, growing together, rising together. Ageing should be no different. It's not just a challenge to navigate, but an opportunity to redefine how we live, work, and thrive in a society where there'll increasingly be more older persons than younger ones. As President Tharman Shanmugaratnam put it: 'An ageing society is an opportunity. We must enable everyone to have contributing, fulfilling and healthy lives, even as they live longer. It will require fundamental shifts... it is a future to be embraced.' As we celebrate Singapore's 60th anniversary, we stand at a pivotal moment: a time to challenge stereotypes around ageing and unlock the possibilities within. Let's come together to reimagine what ageing can mean to each and every one of us – seniors of today, and seniors of tomorrow. This is crucial if we want to build a Singapore where we can all enjoy longer 'living spans'; where longer lives mean healthier, happier, better lives. After all, how well we age – physically, mentally, socially and financially – will be shaped by the choices we make and the habits we begin to cultivate today. The writer is head of DBS Foundation as well as DBS group strategic marketing and communications

Indonesia's military set to produce drugs for public use to lower prices. Will it cause more headaches?
Indonesia's military set to produce drugs for public use to lower prices. Will it cause more headaches?

CNA

time6 days ago

  • CNA

Indonesia's military set to produce drugs for public use to lower prices. Will it cause more headaches?

JAKARTA: Indonesia's plan for the military to produce medicines for public use has sparked alarm among health experts, who question whether the armed forces possess the required expertise and safety protocols. Although facilities run by the army, navy and air force already produce drugs for their soldiers, experts question if they can meet the standards of modern pharmaceutical production. On Jul 22, Indonesian Defence Minister Sjafrie Sjamsoeddin signed an agreement with the country's Food and Drug Supervisory Agency (BPOM) authorising labs run by the army, navy and air force to start producing drugs and medical supplies for civilians. Sjafrie said the military will increase the production capacity of its medical research centres before beginning to produce drugs for the public. The Indonesian government, the minister added, is hoping to launch these military-produced medicines on Oct 5, the 79th anniversary of the country's armed forces. The drugs, he said, will be half the price of those produced by regular pharmaceutical companies and will be available at the 80,000 state-backed Red and White village cooperatives, a programme recently launched by President Prabowo Subianto. 'We will mass produce medicines and ship them to villages at prices which are 50 per cent cheaper than those in the market so people can afford them,' Sjafrie told reporters on Jul 22. "We are thinking of ways to lower the price even more so we could provide free medicines." According to its website, the military has produced 44 types of drugs for internal use, including several paracetamols, pain killers and antibiotics. Officials have not disclosed what medicines or the quantities that would be produced for public use. Experts highlighted the lack of information on the standards and protocols at the military's production facilities. 'Producing medicines requires expertise, precision, sterile labs and strict protocols. How can an institution whose core competence is not in the pharmaceutical sector be allowed to produce medicines for the general public?' Windhu Purnomo, a public health expert from Airlangga University, told CNA. 'What is at stake is the safety, efficacy and quality of the medications produced.' The opaque nature of the military adds to transparency and accountability concerns, observers said. 'If their manufacturing process is faulty, does the health ministry or the BPOM have power over the military? Will those responsible be held accountable? Because the military is not subject to civilian rules and regulations,' said Hermawan Saputra, chairman of the Indonesian Health Expert Association. The pharmaceutical push comes amid a broader political shift under Prabowo, a former defence minister and a retired army general, who has expanded the military's role in civic affairs since he took office last year. Under Prabowo, uniformed men have been appointed to strategic civilian positions inside various ministries, agencies and state-owned enterprises. The military has also been awarded lucrative contracts by the government that range from road construction to cash crop cultivation in various parts of the country. It has even secured catering contracts to supply food to millions of school children and pregnant women under the president's signature free meal initiative. WHAT MEDICINES WILL THE MILITARY PRODUCE? Indonesia has several medical research centres operated by different branches of the armed forces. These centres were built in the 1950s to develop medical procedures, equipment and medicines to treat combat injuries and fight diseases endemic to soldiers' operational areas. The military has not disclosed much information about these research centres, including what types of medication and supplies they produce, how much they produce and where the supplies are distributed. Producing vast quantities of medicines for civilians of different ages and with different health conditions is not the same as manufacturing a limited amount of drugs for a group of young and fit soldiers, experts said. 'The protocols and standards are much stricter for mass produced medicines,' said Hermawan of the health expert association. 'Some chemicals need to be handled, stored and processed in very specific ways. There are strict guidelines to prevent contamination and mix-ups.' Failure to follow these pharmaceutical manufacturing practices can have deadly consequences, he added. In 2022, more than 200 children in various parts of the country died of an acute kidney injury after consuming toxic cough syrup. The poisoning also left several survivors with permanent disabilities including blindness and hearing loss. Last year, an Indonesian court found that lax oversight by the pharmaceutical company Afi Farma and its supplier, Samudra Chemical, caused the syrup to be tainted with ethylene glycol at a concentration that was 1,000 times higher than what is considered safe for consumption. Ethylene glycol is a commonly used chemical in products such as brake fluid and antifreeze. Four officials from Afi Farma and Samudra Chemical were each sentenced to two years in prison and the two companies were ordered to pay millions of dollars in fines and compensation to the victims' families. Samudra Chemical was a new player in the pharmaceutical industry while Afi Farma has been producing medicines since 1985. According to court documents, Samudra was originally selling chemicals to soap manufacturers and had only begun supplying to pharmaceutical companies for a year before the incident occurred. The risk of such poisoning incidents recurring is high if medicines are produced by inexperienced players, experts said. Such episodes, Hermawan said, not only erode the public's trust in the country's health system but also tarnish Indonesia's image internationally. 'Health organisations might think twice about sending free vaccine or drug materials to Indonesia because there is a high chance these materials will not be processed properly,' he said. Taruna Ikrar, chief of the drug supervisory agency BPOM, said his office will ensure that the drugs produced by the military are safe. The Indonesian Armed Forces, he added, is in the process of acquiring the permits and certifications needed to produce and distribute medicines. 'We will make sure the military meets all the requirements, from manufacturing to laboratory standards. We are making recommendations so the military can obtain these certificates,' he said. Indonesian officials have said the military's involvement is needed to keep drug prices low. Existing pharmaceutical players care more about maximising profit than serving people's needs, officials have said, but such an argument misses the mark, experts countered. 'The main problem is 85 per cent of our pharmaceutical ingredients are imported, especially from China and India, and they sometimes involve very long chains of suppliers and intermediaries,' Dicky Budiman, a public health expert from Jakarta's Yarsi University told CNA. This is a factor causing the prices of some drugs in Indonesia to be up to five times that of other countries. 'What the (Indonesian) government should be doing is to build an upstream pharmaceutical industry,' Dicky said. It should provide incentives in the form of tax breaks, subsidies and funding so local pharmaceutical companies, as well as universities and research bodies can develop and produce their own chemical and biological ingredients. 'The government can also force (pharmaceutical) companies to increase their local content through regulations or by prioritising medications with high local content to supply state-run hospitals, health insurance schemes or other government programmes,' he said. Another way to keep medicines affordable is to simplify the distribution chain. The same drug can be sold at starkly different prices at different pharmacies due to various reasons, noted Windhu of Airlangga University. One pharmacy might sell some products cheaply because they are procured directly from the manufacturer. But other products may cost more because the pharmacy may have had to go through layers of distributors and intermediaries. 'Sometimes, a pharmacy will just inflate the price because they are the only ones in town and the nearest competitors are kilometres away,' Windhu added. Each year, the government caps the price of certain generic drugs but experts said this is rarely enforced. Putting a ceiling on how much medicines should cost will force the industry to simplify its distribution chain, Windhu said, as well as curb monopolistic and unethical practices. 'It is no secret that pharmaceutical companies like to provide junkets, lavish events, gifts and even kickbacks to get doctors to prescribe their products, and these costs are ultimately borne by the consumers,' he said. 'It's time the government gets serious about putting a ceiling on how much drugs should be sold, so companies will think twice about these types of practices.' WHEN IS THE MILITARY NEEDED? Despite the outcry, experts acknowledged that the military has valuable assets that can be mobilised to strengthen Indonesia's pharmaceutical industry. With its vast logistical network, disciplined personnel and reach into the most remote corners of the archipelago, the Indonesian Armed Forces could help overcome one of the health sector's most persistent challenges: distribution. 'The military is well equipped to handle distribution to all areas, even the most remote ones. That's different from the private sector which just doesn't have that kind of infrastructure,' Windhu said. The COVID-19 pandemic offered a clear example of how military's logistical abilities and manpower can complement national health efforts. During the pandemic, the military helped transport vaccines, set up field hospitals, and distribute aid to remote regions that proved critical to the overall emergency response. 'The military can be quite useful in times of emergency. However, under normal circumstances, the military should focus on playing a supporting role, filling the gaps which the civilian sector cannot fulfill like (distributing medicines to) remote areas,' Khairul Fahmi, a military expert of the think tank Institute for Security and Strategic Studies told CNA. 'By focusing only on filling the gaps, the military's involvement can strengthen Indonesia's medical sector and not disrupt or be in direct competition with existing pharmaceutical businesses. More importantly, Indonesia can maintain civilian supremacy in the sector.' Health expert Windhu agreed. 'In an emergency where we need to produce huge quantities of medicines in a short amount of time, getting the military involved in pharmaceutical production is justified,' Windhu said.

AstraZeneca quarterly net profit jumps on record US growth
AstraZeneca quarterly net profit jumps on record US growth

Business Times

time29-07-2025

  • Business Times

AstraZeneca quarterly net profit jumps on record US growth

[LONDON] British pharmaceutical giant AstraZeneca on Tuesday (Jul 29) said net profit rose 27 per cent in the second quarter, boosted by record growth in its key US market. Profit after tax rose to US$2.45 billion in the three months to the end of June, the company said in an earnings statement, following its recently announced multi-billion-dollar investment in the United States. Total revenue climbed 12 per cent to a quarterly record of US$14.5 billion, driven by strong cancer drug sales. Amid the threat of President Donald Trump's possible tariffs on pharmaceutical imports, AstraZeneca has unveiled plans to invest US$50 billion in the US by 2030 and has already began moving some of its European production to the US. Chief executive Pascal Soriot said the 'landmark investment reflects not only America's importance but also our confidence in our innovative medicines.' The United States, a critical market for the pharmaceutical industry, accounted for 44 per cent of AstraZeneca's total revenue in the second quarter, with US revenue jumping a record 13 per cent. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The company expects half of its revenue to come from the US by 2030. Trump has ordered an investigation into potential tariffs on pharmaceutical imports, which had so far benefited from exemptions to his sweeping levies on imports from trading partners. He suggested that levies on the sector could reach up to 200 per cent. Washington and Brussels announced a trade agreement on Sunday that places 15 per cent tariffs on pharmaceutical imports from the European Union to the US. Other major pharmaceutical companies – including Swiss giants Roche and Novartis, and France's Sanofi – have also begun shifting investment and production to the United States in recent months. AFP

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store